Shares of Viking Therapeutics have sold off sharply as the market awaits updates on its drug candidates. The company is preparing for the possible FDA approval of its weight loss drug candidate VK2735 ...

Two common GLP-1 medications that are approved by the Food and Drug Administration (FDA) specifically for weight loss are tirzepatide (Zepbound) and semaglutide (Wegovy). Semaglutide was originally ...

Canada's new obesity guidelines signal a shift in food consumption, with GLP-1 drugs impacting how and what Canadians—especially youth—eat.

Tirzepatide is approved for 3 indications in the US: type 2 diabetes, chronic weight management, and obstructive sleep apnea.

Pfizer’s announcement that it will stop developing its oral weight-loss drug gave shares of Wegovy maker Novo Nordisk and ...

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient ...

The two obesity market leaders, with their blockbuster injectables, have left room for an oral, or pill, market to be a new meaningful target for newer players, according to investors. Lilly is the ...

People taking GLP-1 drugs can decrease fat mass while minimizing muscle loss with a few key strategies that include proper ...

The drugmaker said one patient became ill after being treated with its experimental weight-loss drug, danuglipron.

From STAT’s Matthew Herper: Pfizer said this morning that it would stop development of danuglipron, its experimental oral GLP-1 medicine to treat obesity, focusing its efforts on another medicine with ...

Pfizer has axed its oral GLP-1 asset danuglipron after one patient had potential drug-induced liver injury in a phase 1 trial ...

Capping more than two years of stock-gyrating drama, Pfizer said Monday that it would stop development of danuglipron, its ...